Colorectal Cancer : Risk, Diagnosis, and Treatments.

Intro -- COLORECTAL CANCER: RISK, DIAGNOSIS AND TREATMENTS -- COLORECTAL CANCER: RISK, DIAGNOSIS AND TREATMENTS -- Contents -- Preface -- Chapter 1 Distinct and Common Issues in the Psychosocial Adaptation to Cancer Across Cultures -- Abstract -- Colorectal Cancer in Chinese -- Prevalence -- Psycho-Oncological Research in Chinese Populations -- CRC Patients in the West -- Emotional distress -- The impact of physical symptom distress -- The impact of social resources -- Summary -- Sociocultural concerns -- Conceptual framework(s) needed -- Adaptation Process in Chinese CRC Patients -- A Qualitative Enquiry -- 1. Utilization of Medical Resources -- Fatalistic causal attribution -- Control-through-proxy -- 2. Transition of Resource Utilization -- 3. Continuous Resistance to Demands -- a. Shaping personal resources -- b. Developing social resources -- Significance of the Study -- Measuring Social Relational Quality -- Development of the Social Relational Quality Scale (SRQS) -- Concurrent validity -- Convergent and divergent validity -- Known group comparisons -- Significance of the Study -- Intrapersonal and Interpersonal Cancer Perceptions -- Development of the Cancer Experience and Efficacy Scale (CEES) -- Concurrent validity -- Convergent and divergent validity -- Known group comparisons -- Significance of the Study -- From Culture-Specifc Issues to Universal Issues -- Sustainable Positive Affect -- PA as a Psychological Resource -- Resource Loss, Resource Gain -- Operationalizing Resource Change -- Modeling the Impact of PA Change -- Significance of the Study -- Synthesizing Resource Change and Adaptation Trajectories -- Applying the Four Prototypical Trajectories to Cancer -- Predictive Utility of Resource Change -- Growth Mixture Models -- Profiling differential trajectories -- Significance of the Study -- Conclusions.

Cross-Cultural Psycho-Oncological Research -- Social Correlates of Adaptation to CRC -- Stability through Change -- References -- Chapter 2 Adjuvant Chemotherapy for Resected Colorectal Cancer -- Abstract -- Introduction: Adjuvant Chemotherapy - A Balance of Risks and Benefits -- The Evolution of Systemic Adjuvant Chemotherapy in Stage III Disease -- 5-Fluorouracil Monotherapy -- Intravenous Bolus 5-Fluorouracil -- The Role of 5-FU Adjuncts -- Continuous Infusion 5-FU in Stage III Disease -- The Development of Adjuvant Combination Chemotherapy -- Oxaliplatin -- Irinotecan -- Stage II Disease -- Number of Nodes Examined -- T4 Disease -- Pathological Grade -- Lymphatic, Vascular and Perineural Invasion -- Pre-Operative Clinical Characteristics -- Stage II Disease - Conclusions -- Modalities of Adjuvant Chemotherapy Other than Systemic Intravenous Treatment -- Oral Fluoropyrimidines -- Anatomically Targeted Chemotherapy as an Adjuvant Treatment -- COX-2 Inhibitors -- SUBGROUP CONSIDERATIONS IN ADJUVANT CHEMOTHERAPY -- Elderly Patients -- Adjuvant Chemotherapy Following Neoadjuvant Therapy in Rectal Carcinoma -- Timing after Surgery -- Duration of Treatment -- Post-Treatment Surveillance -- Future Directions in Adjuvant Chemotherapy for Colorectal Carcinoma -- Accelerating the Introduction of New Adjuvant Regimens - Disease Free Survival as a Proxy for Overall Survival -- Tools for Risk Stratification Other than Pathological Stage and Grade -- Microsatellite Instability -- Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) -- Gene Expression Profiling -- Monoclonal Antibodies -- Cetuximab -- Bevacizumab -- Edrecolomab -- Conclusions -- References -- Chapter 3 Palliative Care of Colorectal Cancer -- Abstract -- Introduction -- Palliative Anti-Cancer Therapy -- Malignant Bowel Obstruction -- Pathophysiology -- Causes -- Assessment -- Treatment.

Surgery -- Nonoperative interventional strategy -- Venting procedures -- Medical management -- Malignant Ascites -- Clinical Manifestations -- Pathophysiology -- Assessment -- Management -- Diet -- Diuretic therapy -- Paracentesis -- Peritoneovenous shunts -- Tenckhoff catheter -- Investigational Pharmacological Approaches on the Management of Malignant Ascites -- Intraperitoneal Immunotherapy -- Interferon alpha -- Tumor Necrosis Factor-Alpha -- OK-432 -- Anti-VEGF Therapy -- Metalloproteinase Inhibitors -- Octreotide -- Caquexia-Anorexia Cancer Syndrome -- Pathophysiology -- Loss of adipose tissue -- Loss of skeletal muscle -- Underlying Causes -- Assessment -- Management -- Agents affecting appetite -- Agents Affecting Cachectic Mediators or Signaling Pathways -- EPA -- -hydroxy- -methylbutyrate (HMB) -- Thalidomide -- Nonsteroidal anti-inflammatory agents -- Pain -- Pathophysiology -- Causes -- Assessment -- Management -- Last Hours of Life -- Food and Water Intake -- Neurological Dysfunction -- Respiratory Dysfunction -- Cardiac Dysfunction, Renal Failure and Peripheral Hypoperfusion -- Conclusion -- References -- Chapter 4 Gene Variants and Gene Products Encoded in the Central Part of the MHC are Strongly Associated with both the Risk and the Prognosis of Colorectal Cancer -- Abstract -- Introduction -- Genetic Risk Factors of Colorectal Cancer -- The 8.1 Ancestral Hyplotype -- Patients and Controls Tested -- Methods Used to Determine Carrier State of AH8.1 -- Other Laboratory Methods -- Statistical analysis -- Part I. Carriers of the so-Called 8.1 Ancestral Haplotype Are at an Excessive Risk for Colorectal Cancer -- Reasons for Performing the Study -- Results: High Risk of Colorectal Cancer Is Associated with the Carrier State of the 8.1 Ancestral Haplotype -- Discussion of the Findings of this Part of the Study.

Comparison of Colorectal Cancer Risk Associated with the Carrier State of the 8.1 Ancestral Haplotype with Recently Reported other Polymorphisms -- Part 2. Carrier State of the 8.1 Ancestral Haplotype Strongly Influences the Levels of Igg Type Antibodies to 70 Kda Heat Shock Proteins (Hsp70) in Male Patients with Colorectal Cancer -- Reasons for Performing this Study -- Results: Differences in the Serum Concentration of ANTI-HSP70 and Soluble HSP70 between Carriers and Non-Carriers of AH8.1 -- Discussion of This Part of the Study -- Part 3. Serum Level of Soluble 70 kDa Heat Shock Protein Is Associated with High Mortality in Patients with Colorectal Cancer Without Distant Metastasis -- Reasons for Performing the Study -- Results: Prediction of the Survival of Patients with Non-Metastatic Colorectal Cancer According to the Serum Level of Soluble HSP70 -- Discussion of the Results of This Part of the Study and Their Usefulness in Predicting Survival, Compared to Other Laboratory Parameters -- Conclusions -- References -- Chapter 5 The Role of Cytoreduction as a Multidisciplinary Treatment Modality for Metastatic Colorectal Cancer -- Abstract -- Introduction -- 1. Rationale for Cytoreduction in Cancer Therapy -- 2. Classification of Cytoreduction -- 3. Approach for Cytoreduction in Colorectal Cancer -- 4. Indications for Cytoreduction in CRC -- 4.1. Resectable Tumor (Primary and Metastatic) -- 4.1.1. Resectable primary tumor -- 4.1.2. Resectable metastatic tumors -- 4.2. Unresectable Tumor (Primary and Metastatic) -- 4.2.1. Unresectable primary tumor -- 4.2.1.1. Unresectable primary tumor with no distant metastases -- 4.2.1.2. Unresectable primary tumor with distant metastases -- 4.2.2. Unresectable metastatic tumor -- 4.2.2.1. Unresectable multiple metastases in a single organ -- 4.2.2.2. Unresectable multiple metastases in several organs.

5. Timing of Cytoreduction in CRC -- 5.1. Primary Cytoreduction (Figure 2-1) -- 5.2. Secondary Cytoreduction (Figure 2-2) -- 6. Outcome of Secondary Cytoreduction in our Series -- 7. Discussion -- References -- Chapter 6 Prognostic Factors of Survival in Stage IIB-III and IV Colorectal Cancer -- Abstract -- Introduction -- Patients and Methods -- Results -- Conclusion -- Introduction -- Part A. Prognostic Factors of Survival in Metastatic (Advanced) Colorectal Cancer -- Objectives -- Methods -- Conclusion -- Part B. Prognostic Factors of Survival in Dukes B2 and C Colorectal Cancer -- Rationale -- Methods -- Conclusion -- References -- Chapter 7 Serum CSE1L and CEA for Prognosis of Metastatic Colorectal Cancer -- Abstract -- Commentary -- Conclusion and Perspectives -- References -- Chapter 8 Radiofrequency Ablation as a Novel Therapy for Pulmonary Metastasis from Colorectal Cancer -- Abstract -- References -- Chapter 9 Hepatectomy for Liver Metastases from Colorectal Carcinoma: Comparison to Liver Metastases from Gastric Carcinoma -- References -- Index.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.